Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956114 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL535754 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL83498 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL27699982 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL27680704 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL24880067 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| Hydrochloric Acid SCHEMBL28365190 | 0.98 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL9482122 | 0.98 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| Water SCHEMBL27834068 | 0.98 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| Water SCHEMBL28794479 | 0.98 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1920773-A1 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2008-05-14 | — | — | EP | claimed |
| EP-0963200-B9 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1586322-A2 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2005-10-19 | — | — | EP | claimed |
| EP-0963200-B1 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2004-12-09 | — | — | US | claimed |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2003-10-09 | — | — | US | claimed |
| JP-2002513391-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | claimed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | claimed |
| US-20250163172-A1 | Combination Treatment for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-22 | — | — | US | disclosed |
| US-20250122297-A1 | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12234293-B2 | Treatment for primary amyloidosis with anti-BCMA binding protein | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-12227585-B2 | Anti-BCMA antibody drug conjugate combination treatment for cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| CN-118557697-A | Combination therapy for cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-1586322-A2 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-0963200-B1 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2004-12-09 | — | — | US | disclosed |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227585-B2 | Anti-BCMA antibody drug conjugate combination treatment for cancer | CD79B, CD22, CD40 | ALDH1A1 3770/4885PKM 3103/4885HPGD 2476/4885 |
| US-20250122297-A1 | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer | CD79B, CD22, CD40 | ALDH1A1 3770/4885PKM 3103/4885HPGD 2476/4885 |
| US-20250163172-A1 | Combination Treatment for Cancer | SERPINA6, BCL6, BCOR | ALDH1A1 4112/4885PKM 4056/4885HPGD 2557/4885 |
| US-12234293-B2 | Treatment for primary amyloidosis with anti-BCMA binding protein | SERPINA6, BCL6, HSPBP1 | ALDH1A1 4175/4885PKM 3994/4885HPGD 3344/4885 |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | ALDH1A1 436/4885PKM 3731/4885HPGD 31/4885 |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | ALDH1A1 436/4885PKM 3731/4885HPGD 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.